NBP
NASDAQNovaBridge Biosciences
News25/Ratings1
News · 26 weeks53-65%
2025-10-262026-04-19
Mix3990d
- Insider19(49%)
- SEC Filings10(26%)
- Other5(13%)
- Leadership3(8%)
- Analyst1(3%)
- Earnings1(3%)
Latest news
25 items- INSIDERSEC Form 3 filed by new insider Hagler Mark Arnold3 - NovaBridge Biosciences (0001778016) (Issuer)
- SECSEC Form 6-K filed by NovaBridge Biosciences6-K - NovaBridge Biosciences (0001778016) (Filer)
- PRNovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline ValueSeasoned Biopharma leader bringing deep commercial experience to shape and inform corporate strategy, clinical trial design and business development discussionsStrong industry reputation and commercial track record in high-value pharmaceutical markets including oncology and ophthalmologyStrengthens NovaBridge's leadership team as the Company advances givastomig, a potential first-in-class Claudin 18.2 x 4-1BB bispecific antibody for first line (1L) gastric cancer, toward registrational pivotal studies and continues to advance VIS-101, purpose-designed, potential best-in-class, dual VEGF-A x ANG-2 inhibitor for wet AMD ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- NovaBridge Bioscienc
- INSIDERAmendment: SEC Form 3 filed by new insider Xu Cong Claire3/A - NovaBridge Biosciences (0001778016) (Issuer)
- SECSEC Form 6-K filed by NovaBridge Biosciences6-K - NovaBridge Biosciences (0001778016) (Filer)
- SECSEC Form 20-F filed by NovaBridge Biosciences20-F - NovaBridge Biosciences (0001778016) (Filer)
- PRNovaBridge Reports Full Year 2025 Financial Results and Provides Business UpdateSuccessful transformation to global biotech platform with two mid-stage potential best-in-class/first-in-class programs, givastomig and VIS-101, with compelling proof-of-concept dataGivastomig, a potential best-in-class/first-in-class Claudin 18.2-directed bispecific antibody for gastric cancer, has shown robust and durable responses with broad CLDN18.2 activity, favorable safety, as well as potential eligibility for FDA's Accelerated Approval Pathway with potential initiation of a registrational Phase 3 trial as early as Q4 2026VIS-101, a potential best-in-class VEGF-A X ANG-2 inhibitor for wet-AMD, produced rapid, robust and durable responses in treatment naïve wet-AMD patients, and is poi
- INSIDERSEC Form 3 filed by new insider Yang Conor Chia-Hung3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Chu Denny Hsueh Wen3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Dennis Phillip Andrew3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lin Liwei Lorraine3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Fu Xi-Yong3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Zhang Xiaofan Neo3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lei Ming Kyler3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Wu Joanna Xuqiong3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Fu Wei3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cao Sean Wuxiong3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cunningham Emmett3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Xu Cong Claire3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Liu Xin3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Zhang Adeline Yi3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Woo Ian Ying3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lenz Robert A.3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Au Chun Kwok Alan3 - NovaBridge Biosciences (0001778016) (Issuer)
- SECSEC Form 6-K filed by NovaBridge Biosciences6-K - NovaBridge Biosciences (0001778016) (Filer)